Mumbai: Huwel Lifesciences has partnered with Avio Smart Market Stack Limited (ASMS) to mark a significant step in its global growth journey, onboarding a Singapore-based regional commercialization partner to expand its footprint across Southeast Asia.
This strategic move by Huwel Lifesciences is aimed at strengthening market access and driving business growth in one of the world’s fastest-growing healthcare regions.
The collaboration between Huwel Lifesciences and ASMS is designed to establish a scalable export platform across key Southeast Asian markets, including Singapore, Indonesia, Malaysia, Thailand, Vietnam, and the Philippines.
These regions are witnessing increasing healthcare investments, growing awareness around diagnostics, and rapid expansion of laboratory infrastructure, making them ideal markets for Huwel Lifesciences’ advanced diagnostic solutions.
Southeast Asia is emerging as a high-growth healthcare opportunity zone globally, supported by large populations, rising urbanization, expanding medical tourism, and a stronger focus on infectious disease management and public health preparedness.
Also Read: AVIO Agritech Expansion: ASMS Strengthens Agri-Commerce Network with AYOU’s Hyderabad Rollout
Governments across these countries are actively investing in screening infrastructure, laboratory modernization, women’s health diagnostics, and decentralized testing systems.
This evolving landscape presents a strong opportunity for Huwel Lifesciences to deploy its innovative technologies at scale.
Under the terms of the partnership, ASMS will lead commercial execution, including strategic sales development, channel partnerships, and regional rollout planning.
Huwel Lifesciences Will Focus on Technology Development, Manufacturing, Regulatory Support, Continuous Product Innovation to Meet Regional Healthcare Demands
The expansion will be driven by Quantiplus, the flagship molecular diagnostics platform from Huwel Lifesciences, which will serve as the lead product for market entry.
Known for its affordability, scalability, and clinical reliability, Quantiplus is well-suited for institutional, laboratory, and public health applications, especially in high-volume and cost-sensitive healthcare systems across Southeast Asia.
N Vidhya Sagar Reddy, Managing Director, ASMS, said: “This collaboration marks an important step in building our healthtech vertical as a long-term growth driver.
By leveraging our strengths in market development and execution, we aim to create a strong commercialization ecosystem for Huwel’s innovations across Southeast Asia. It also aligns with our broader vision of building diversified, future-ready businesses across healthcare, agriculture, and digital commerce.”
Following the initial rollout, the partnership plans to introduce additional solutions from the Huwel Lifesciences diagnostics portfolio.
These include portable testing platforms, decentralized molecular systems, rapid screening solutions, and specialized diagnostic applications tailored to address region-specific healthcare needs.
For ASMS, this collaboration further strengthens its emerging healthtech vertical, complementing its existing focus on financial inclusion and agritech initiatives.
The company has identified healthcare technology as a key long-term growth driver with both domestic and international potential, making its alliance with Huwel Lifesciences strategically significant.
The partnership reflects a broader vision of combining India’s innovation and manufacturing strengths with agile international commercialization networks.
By integrating the scientific capabilities of Huwel Lifesciences with ASMS’s market execution expertise, the collaboration aims to establish a strong export engine for next-generation healthcare solutions.
This move also reinforces India’s growing position as a global hub for advanced and cost-efficient diagnostics, with Southeast Asia serving as a critical milestone in the international expansion strategy of Huwel Lifesciences.
